letter to the editor HER2 overexpression on immunohistochemistry (IHC). Treatment with docetaxel and trastuzumab allowed a major bone and local response. Surgical resection of the chest wall showed residual HR-positive invasive carcinoma, but without HER2 overexpression. We report three clinical cases raising the issues of intratumoral heterogeneity of HER2 expression, the natural history of this particular subset of tumors and consequently their management at both early and advanced stages. HER2 status is usually not modified by therapy [4] . In a consecutive series of >600 HER2-positive breast cancers treated at Institut Curie, 5% exhibited intratumoral heterogeneity of HER2 overexpression, as shown by both IHC, according to French validated methods [5] and FISH (Figure 1 ). None of these three patients received trastuzumab in the adjuvant setting. These cases show that HER2 status in metastases may be similar to that of the primary tumor (i.e. heterogeneous, case 3) or different. In case 2, liver metastases exhibited FISH-confirmed HER2 gene amplification, when HER2 status was deemed heterogeneous in the primary tumor. We postulate that such cases may represent the proof that specific cell subclones may evolve separately. HER2-positive cells may account for metastatic progression. If this is the case, biopsies should be carried out on metastases from primary tumors with heterogeneous HER2 expression. Cases 1 and 3 also demonstrate that HER2 status may apparently 'change' during HER2-targeted therapy. The first hypothesis to explain this effect is mainly a selection of one preferential subclone in the residual tumor harboring a different HER2 status than the majority of the cells in the primary tumor. Although the intimate pharmacodynamic mechanisms of trastuzumab and lapatinib have not been fully elucidated, complete eradication of HER2-positive cells is a possible hypothesis [6] . Consequently, this provides a new rationale concerning the duration of HER2-targeted therapy, which is currently being challenged by the French PHARE clinical trial [7, 8] (http:// www.e-cancer.fr/Les-Essais-cliniques/Essai-PHARE/op_1-it_779-la_1-ve_1.html). This issue also raises the problem of the determination of surrogate markers of the efficacy of anti-HER2 therapy, particularly in the adjuvant setting, or after complete remission from HER2-positive metastatic disease, as the heterogeneity of HER2 status in breast carcinoma opens a challenging field of research. 
